{"id":"sofosbuvir-ribavirin-and-stribild","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Anemia"},{"rate":"10-15","effect":"Insomnia"},{"rate":"5-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, directly blocking viral replication. Ribavirin is a broad-spectrum antiviral nucleoside analog that enhances immune response and inhibits viral polymerase. Stribild is an HIV integrase inhibitor combined with a pharmacokinetic booster and two nucleoside reverse transcriptase inhibitors, used when HCV/HIV co-infection is present. Together, these agents provide direct-acting antiviral therapy for HCV with concurrent antiretroviral coverage.","oneSentence":"This combination targets hepatitis C virus (HCV) through multiple mechanisms: sofosbuvir inhibits viral RNA polymerase, ribavirin is a nucleoside analog that disrupts viral replication, and Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) is an antiretroviral combination for HIV co-infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:43.888Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1-6)"},{"name":"Hepatitis C virus infection in HIV co-infected patients"}]},"trialDetails":[{"nctId":"NCT02220868","phase":"PHASE4","title":"Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study","status":"COMPLETED","sponsor":"Saint Michael's Medical Center","startDate":"2014-07","conditions":"Hepatitis C Infection, HIV Infection","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sofosbuvir, Ribavirin, and Stribild","genericName":"Sofosbuvir, Ribavirin, and Stribild","companyName":"Saint Michael's Medical Center","companyId":"saint-michael-s-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination targets hepatitis C virus (HCV) through multiple mechanisms: sofosbuvir inhibits viral RNA polymerase, ribavirin is a nucleoside analog that disrupts viral replication, and Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) is an antiretroviral combination for HIV co-infection. Used for Chronic hepatitis C virus infection (genotypes 1-6), Hepatitis C virus infection in HIV co-infected patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}